Ultrasound monitoring for Takayasu arteritis
Part of Heart & circulation, Skin clinical trials.
This study tests a new ultrasound scoring system to monitor disease activity in people with Takayasu arteritis. It aims to see if ultrasound can reliably track the disease, which might help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of Takayasu arteritis.
- Your disease must be active, shown by at least two of: new or worsening symptoms, high inflammation blood tests, or imaging signs of inflammation.
- You must be able to have ultrasound exams of your blood vessels.
- You must agree to give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
This trial tests an oral medication called deucravacitinib (which is already used for psoriasis) to see if it can calm inflammation in Takayasu's arteritis. If you have active disease despite current treatment, this may offer a new option to help control symptoms and prevent damage.
This UK-based study uses a questionnaire to learn about how people with Takayasu arteritis (a rare type of vasculitis) are treated and what they think about their care. If you have TAK, your answers can help doctors understand how to better manage this condition.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Hear when a new Takayasu Arteritis (TAK) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.